Rivera R, Vanaclocha F, Herranz P

Language: Spanish
References: 19
Page: 10-17
PDF size: 242.79 Kb.

ABSTRACT

The use of biological therapy has revolutionated the treatment of many inflammatory diseases; one of them, psoriasis. But not always patients respond adequately to these treatments. One of the reasons of lost of efficacy is immunogenicity, as a result of the appearance of antibodies against these agents. Furthermore it is a reason for the adverse events to happen. Until now in clinical practice we did not have the adequated tools to detect these antidrug-antibodies, nowadays we have them. There are few studies in psoriatic patients to know the relevance of these detections. In this paper we want to review the significance of the immunogenicity in the biological treatments and their value in clinical practice.

REFERENCES

1. Biobadaderm Informe de Resultados 2013 (Registro Español de Acontecimientos Adversos en Terapias sistémicas en psoriasis). Fundación AEDV, Madrid 2013.

2. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009; 21: 211-215.

3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Wolbink GJ, de Vries N, Tak PP et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum. 2009; 60: 2541-2542.

4. Jullien D. Anticorps anti-médicament, auto-anticorps et traitements biologiques du psoriasis. Ann Dermatol Venereol. 2012; 139: S58-S67.

5. Martín ME, Plasencia C, Balsa A. Cambio a un segundo anti-TNF cuando ha fracasado el primero (switching) en la artritis reumatoide. ¿Qué nos aportan los nuevos datos sobre inmunogenicidad? Reumatologia Clínica. 2011; (Supl 6): 23-28.

6. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-especific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013; 72: 165-178.

7. Infliximab-Remicade. European summary of Product Characteristic: EMEA (www.ema.europa.eu) [Consultado: 21-3-2013].

8. Adalimumab-Humira. European summary of Product Characteristic: EMEA (www.ema.europa.eu) [Consultado: 21-3-2013].

9. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011; 63 (4): 877-883.

10. Etanercept-Enbrel. European summary of Product Characteristic: EMEA (www.ema.europa.eu) [Consultado: 21-3-2013].

11. Ustekinumab-Stelara. European summary of Product Characteristic: EMEA (www.ema.europa.eu) [Consultado: 21-3-2013].

12. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010; 146: 127-132.

13. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma through levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013; 40 (1): 39-42.

14. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011; 50 (8): 1445-1452.

15. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012; 71: 1955-1960.

16. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011; 70: 284-288.

17. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheumatism. 2011; 63: 867-870.

18. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305: 1460-1468.

19. Steenholdt C, Brynskov J, Thomsen O, Munch LK, Fallinborg J, Christensen LA et al. Treatment of secondary infliximab failure in Crohn’s disease based on serum levels of infliximab and antibodies against infliximab: the danish study of optimazing infliximab therapy in Crohn’s disease (Do it Crohn) randomized clinical trial. Digestive week. Orlando Florida, EUA 2013.